Epidiolex

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines
$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country

Epidiolex Recent News

Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada
Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants conducted by consumer insights company Antenna, reported Cannabiz.
|
Unlocking Smiles: New Study Reveals Oral CBD As Safe & Effective Opioid Alternative For Dental Pain
In groundbreaking research published this month in the Journal of Dental Research, scientists from Rutgers University and the University of Texas revealed that CBD, a cannabis compound could offer a potent and safe alternative to opioids for managing acute dental pain
|
Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates
Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a measure to legalize medical products derived from cannabis, simultaneously emphasizing the country's existing restrictions on the use of other marijuana products.
|
Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year.
|
Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group
Is the battle for medical marijuana legalization in North Carolina over for this year? Some groups say yes, some say no. Here is what happened.
|
UK Mom's Concern As No Doctor Will Prescribe Cannabis For Her Daughter's 300 Daily Seizures
Unexpected falls, stiff muscles, dazed behavior, memory gaps, mumbling or no response, sudden bursts of anger and fear are all symptoms of epilepsy, which is one of the most common childhood brain disorders. Now imagine your own child having up to 300 seizures a day.
|
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various adverse reactions to drugs in general. In the report, the agency notes that as many as 10 people have died from CBD and more than 870 experienced adverse reactions.
|
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from tuberous sclerosis complex (TSC). This mea
|
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS
|
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.
|
Cannabis Drugs Market Could Exceed $2013.42B By 2030, Says New Report
According to new market research published by Growth+Reports, a part of GRG Health, a global healthcare knowledge service company, the cannabis drugs market is expected to grow at a CAGR of 59% from 2021 to reach US$ 2013.42 billion
|
Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit
A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision of the country's policy on drugs to enable the import, manufacture and use of medicines derived from cannabis.
|
Kansas Patients Now Have Access To Medicinal Cannabis Without A State Law
On June 2, Governor Laura Kelly (D) signed new legislation that would allow Kansans to obtain prescription drugs derived from cannabis-related products.
|
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel Concepts (doing business as Free State Oils), Hope Botanicals, Plantacea LLC (doing business as Kahm CBD
|
Jazz Pharma Getting New State-Of-The-Art Facility For Cannabis-Based Research And Production
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million.&nb
|
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022.
|
Jazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02B
Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its financial results on Tuesday for the second quarter of 2021 with total revenue of $751.81 million, up by 34% from $562.43 million in the 
|
Does Big Business Provide A Better Look Into Cannabis Reform Than Capitol Hill? Operators Believe So.
Cannabis operators and executives tell Benzinga that the movement of private and public companies may serve as a better indicator of regulatory activity than the federal government. At the very least, they say that the industry has made advancements so far without the efforts of Capitol Hill.
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved